In RCC, ICI showed promising results (124), and Cabozantinib, a potent inhibitor of VEGF, AXL and MET receptors, has also been approved for first line use with Nivolumab in patients with advanced RCC (125). This evidence concerns the gene VEGFA and renal cell carcinoma.